medigraphic.com

2003, Número 4

<< Anterior Siguiente >>

Arch Cardiol Mex 2003; 73 (4)


El 17ß-estradiol modula los efectos de los cambios de la contractilidad vascular producidos por la insulina

Nava P, Carbó R, Guarner V

Idioma: Ingles.
Referencias bibliográficas: 45
Paginas: 253-260
Archivo PDF: 101.09 Kb.


RESUMEN

Los estrógenos protegen a la mujer contra enfermedades vasculares periféricas y centrales; sin embargo, su papel se pierde con la diabetes. Los estrógenos reducen la tensión en las arterias mediante cambios en el calcio intracelular en células endoteliales y musculares lisas y la regulación de la óxido nítrico sintasa en células endoteliales. La insulina incrementa la liberación de endotelina-1 (ET-1) en células endoteliales aumentando la fuerza generada por las arterias. En este estudio se examina si el 17b-estradiol (E2b) modula los cambios en la contractilidad inducidos por insulina en las arterias femorales y coronarias. Las arterias se obtuvieron de ratas Wistar macho y se colocaron en cámaras para tejido aislado para perfundirse in vitro con distintas concentraciones de insulina y estrógenos estimulando la contracción con KCl 40 mmol/L. La insulina elevó la fuerza de la contracción inducida por KCl. Este incremento desapareció cuando se eliminó el endotelio. El E2b disminuyó la tensión desarrollada por las arterias conforme se aumentó la dosis y el efecto desapareció al quitar el endotelio. El incremento en la tensión por insulina disminuyó con E2b. En conclusión el efecto de la insulina sobre las arterias femorales y coronarias se encuentra modulado por el E2b.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Nabulsi A, Folsom AR, White A, Patsch W, Heiss G, Wu KK, et al: Association of hormone-replacement therapy with various cardiovascular risk factors in post-menopausal women. N Engl J Med 1993; 328: 1069-1075.

  2. Kafonek SD: Postmenopausal hormone replacement therapy and cardiovascular risk reduction. Drugs 1994; 47: 16-24.

  3. Kannel WB: Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: 3S-10S.

  4. Barret-Connor E, Grady D: Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 55-72.

  5. Carson-Jurica MA, Schrader WT, O’Malley BW: Steroid receptor family: structure and functions. Endocr Rev 1990; 11: 201-220.

  6. Nabekura J, Oomura Y, Minami T, Mizuno Y, Fukuda A: Mechanism of the rapid effect of 17 beta-estradiol on medial amygdala neurons. Science 1986; 233: 226-228.

  7. Evans R: The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889-895.

  8. Epstein M, Sowers JR: Diabetes mellitus and hypertension. Hypertension 1992; 19: 403-418.

  9. Rubio-Gayosso I, Sierra-Ramirez A, García-Vazquez A, Martinez-Martinez A, Munoz-García O, Morato T, et al: 17b-Estradiol increases intracellular calcium concentration through a short-term and nongenomic mechanism in rat vascular endothelium in culture. J Cardiovasc Pharmacol 2000; 36: 196-202.

  10. Rodriguez J, Garcia de Boto MJ, Hidalgo A: Mechanisms involved in the relaxant effect of estrogens on rat aorta strips. Life Sci 1996; 58: 607-615.

  11. Prakash YS, Togaibayeva A, Kannan MS, Miller VM, Fitzpatrick LA, Sieck GL: Estrogen increases Ca2+ efflux from female porcine coronary arterial smooth muscle. Am J Physiol 1999; 276: H926-H934.

  12. Nava P, Masso F, Collados T, Guarner V: Endothelin mediation of insulin and glucose-induced changes in vascular contractility. Hypertension 1997; 30: 825-829.

  13. Kannel WB: Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987; 114: 413-419.

  14. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 2001; 37: 1053-1059.

  15. Levy J, Zemel MB, Sowers JR: Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension. Am J Med 1989; 87: 7S-16S.

  16. Resnick L: Hypertension and abnormal glucose homeostasis. Am J Med 1989; 87: 17S-22S.

  17. Barbagallo M, Gupta RK, Dominguez LJ, Resnick LM: Cellular ionic alterations with age: relation to hypertension and diabetes. J Am Geriatr Soc 2000; 48: 1111-1116.

  18. Reaven GM, Hoffman BB: Hypertension as a disease of carbohydrate and lipoprotein metabolism. Am J Med 1989; 87: 2S-6S.

  19. Park JY, Takahara N, Gabriele A, Chou E, Naruse K Suzuma K, et al: Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 2000; 49: 1239-1248.

  20. Oliver FJ, de la Rubia G, Feener EP, Lee ME, Loeken MP, Shiba T, et al: Stimulation of endothelin-1 gene expression by insulin in endothelial cells. J Biol Chem 1991; 266: 23251-23256.

  21. Piatti PM, Monti LD, Conti M, Baruffaldi L, Galli L, Phan CV, et al: Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. Diabetes 1996; 45: 316-321.

  22. Kuboki K, Jiang ZY, Takahara N, Ha SW, Igarashi M, Yamauchi T, et al: Regulation of endothelial constitutive nitric oxidesynthase gene expression in endothelial cells and in vivo. A specific vascular action of insulin. Circulation 2000; 101: 676-681.

  23. Kahn AM, Husid A, Odebunmi T, Allen JC, Seidel CL, Song T: Insulin inhibits vascular smooth muscle contraction at site distal to calcium concentration. Am J Physiol 1998; 5: E885-E892.

  24. Lembo G, Iaccarino G, Vecchione C, Barbato E, Morisco C, Monti F, et al: Insulin enhances endothelial adrenergic vasorelaxation by a pertussis toxin mechanism. Hypertension 1997: 1128-1134.

  25. Grodstein F, Manson JE, Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the nurses’ health study. A prospective, observational study. Ann Intern Med 2001; 135: 1-8.

  26. Binder EF, Williams DB, Schechtman KB, Jeffe DB, Kohrt WM: Effects of hormone replacement therapy on serum lipids in elderly women. a randomized, placebo-controlled trial. Ann Intern Med 2001; 134: 754-760.

  27. Nickenig G, Wassmann S, Bohm M: Regulation of the angiotensin AT1 receptor by hypercholesterolaemia. Diabetes Obes Metab 2000; 2: 223-228.

  28. Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al: HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37: 1450-1457.

  29. Gilligan DM, Badar DM, Panza JA, Ouyyumi AA, Cannon RO 3rd: Acute vascular effects of estrogen in postmenopausal women. Circulation 1994; 90: 786-791.

  30. Zacharia LC, Jackson EK, Gillespie DG, Dubey RK: Increased 2-methoxyestradiol production in human coronary versus aortic vascular cells. Hypertension 2001; 37: 658-662.

  31. Rupnow HL, Phernetton TM, Shaw CE, Modrick ML, Bird IM, Magness RR: Endothelial vasodilator production by uterine and systemic arteries. VII. Estrogen and progesterone effects on eNOS. Am J Physiol (Heart Circ Physiol) 2001; 280: H1699-705.

  32. Kitazawa T, Hamada K, Kitazawa K, Gaznabi AK: Non-genomic mechanism of 17 beta-oestradiol-induced inhibition of contraction in mammalian vascular smooth muscle. J Physiol 1997; 499: 497-511.

  33. Yallampalli C, Dong Y-L: Estradiol-17ß inhibits nitric oxide synthase (NOS)-II and stimulates NOS-III gene statement in the rat uterus. Biol Reprod 2000; 63: 34-41.

  34. Ropero AB, Fuentes E, Rovira JM, Ripoll C, Soria B, Nadal A: Non-genomic actions of 17beta-oestradiol in mouse pancreatic beta-cells are mediated by a cGMP-dependent protein kinase. J Physiol 1999; 521: 397-407.

  35. Morley P, Whitfield JF, Vanderhyden BC, Vanderhyden BC, Tsang BK, Schwartz JL: A new nongenomic estrogen action: the rapid release of intracellular calcium. Endocrinology 1992; 131: 1305-1312.

  36. Raddino R, Manca C, Poli E, Bolognesi R, Visioli O: Effects of 17 beta-estradiol on the isolated rabbit heart. Arch Int Pharmacodyn Ther 1986; 281: 57-65.

  37. Ruehlmann DO, Mann GE: Rapid non-genomic vasodilator actions of oestrogens and sex steroids. Curr Med Chem 2000; 7: 533-541.

  38. Meyer R, Linz KW, Surges R, Meinardus S, Vees J, Hoffmann A, et al: Rapid modulation of L-type calcium current by acutely applied oestrogens in isolated cardiac myocytes from human, guinea-pig and rat. Exp Physiol 1998; 83: 305-321.

  39. Colburn P, Buonassisi V: Estrogen-binding sites in endothelial cell cultures. Science 1978; 201: 817-819.

  40. Tamura K, Yamaguchi K, Kogo H: 17Beta-estradiol inhibits ovariectomy-induced expression of inducible nitric oxide synthase in rat aorta in vivo. Life Sci 2000; 66: PL 259-264.

  41. Gonzales RJ, Walker BR, Kanagy NL: 17beta-estradiol increases nitric oxide-dependent dilation in rat pulmonary arteries and thoracic aorta. Am J Physiol Lung Cell Mol Physiol 2001; 280: L555-564.

  42. Gorodeski GI: Calcium regulates estrogen increase in permeability of cultured CaSki epithelium by eNOS-dependent mechanism. Am J Physiol Cell Physiol 2000; 279: 495-505.

  43. Yang S, Bae L, Zhang LJ: Estrogen increases eNOS and NOx release in human coronary artery endothelium. Cardiovasc Pharmacol 2000; 36: 242-247.

  44. Toung TK, Hurn PD, Traystman RJ, Sieber FE: Estrogen decreases infarct size after temporary focal ischemia in a genetic model of type 1 diabetes mellitus. Stroke 2000; 31: 2701-2706.

  45. Haefliger J, Flammer TF, Luscher: Nitric oxide and endothelin-1 are important regulators of human ophthalmic artery. Invest Ophthalmol Visual Sci 1992; 33: 2340-2343.




2020     |     www.medigraphic.com